REGISTER NOW

Still a few seats available!

HOTEL RESERVATION

Grange Tower Bridge Hotel
P.: + 44 (0) 0207 959 5000
E: towerbridge.groups@grangehotels.com
Please quote CTO169015 when making your booking

REGISTER FOR BOTH THE 15th BIOSIMILAR MEDICINES CONFERENCE AND THE 13th LEGAL AFFAIRS CONFERENCE AND GET A 10% DISCOUNT!

If you are a registered participant and wish to enrol a further new* delegate, please contact Lucia Romagnoli to obtain a 10% discount. This will be applied as soon as the new registration is confirmed.

* This 10% discount is applicable for those who have never attended our event before or who have not attended our event for the past 2 years.

video-mes2Welcome to our 2017 Biosimilar Medicines Conference webpage!

Come and join us for what has become, over the years, the annual gathering of international experts in the field of biosimilar medicines and a flagship event for an ever-growing number of stakeholders.

Following the successful event in 2016 when we celebrated the 10th anniversary of the launch of the first biosimilar medicine in the EU, the Biosimilar Medicines Group will organise its 2017 annual conference ‘Biosimilar Medicines: a game changer for healthcare sustainability’, in London on 23 & 24 March.

Our 15th Biosimilar Medicines Conference will provide insight into the current state of play in the EU and stimulate debate, in a multi-stakeholder setting, on the important role of biosimilar medicines in the sustainability of healthcare systems.

Beyond a comprehensive outlook of key European market access policies, a panel of renowned international regulators will outline the key recent developments in regulatory science and regulatory policy in the EU and other international jurisdictions. Particular emphasis will be placed on strengthening the link between regulators and medical communities as an essential basis for greater understanding and acceptance of biosimilar medicines.

What participants said about the 2016 edition

Fantastic conference! Excellent content, great contacts and an opportunity to actually meet company and association colleagues I only knew via teleconferences.

twitter-128#BIOS17

20160428 Annual Biosimilar Medicines Group Conference

graph2

Topics

Session B1/L6 – A competitiveness boost: how to strengthen biosimilar medicine developers in Europe?

Session B2 – What are the trends for the use of Biosimilar Medicines in medical practice in Europe?

  • Market trends and policy frameworks – impact of biosimilar competition
  • Ongoing stakeholder communities’ information and education initiatives
  • Experience and Real World Evidence as an integral part of policy making

Session B3 – Improving Access to modern therapies: What can we learn from gainsharing practices?

  • Illustrative examples of gainsharing schemes from across Europe
  • Solving the equation: when medical use of biosimilar medicines directly or indirectly benefits physicians or hospitals
  • Best gainsharing practices

Session B4 – What is sustainability? – A multi-stakeholder approach to securing the future of healthcare systems

  • Definition of healthcare sustainability
  • Stakeholders’ role in healthcare sustainability
  • Lookout and longer-term perspective: multi-stakeholder collaboration

Session B5 – Connecting the Dots? Towards International Regulatory Convergence

  • Key international regulators from the European Union, the United States, South Korea and Brazil
  • Extrapolation of indications, statistical analyses of analytical similarity data, immunogenicity evaluation
  • Importance of PK/PD studies, statistics in Clinical Trials

Session B6 – Convergence between Regulatory science and Medical practice: closing the loop

  • European regulators’ positions on interchangeability and public study results
  • Sharing and communicating real world evidence and pharmacovigilance data
  • Good practice to reduce the gap between regulatory science and medical practice

Session B7 – What are the Key New International Developments? Any Regulatory Questions? Ask the Regulators!

  • High level summary of international regulatory developments affecting biosimilar applications
  • Unique opportunity for the audience to address scientific and regulatory questions directly to the regulators

graph1

question

To make the most of this unique opportunity, questions should be formulated generally and be sent by 8 March 2017 to Julie Marechal

PROGRAMME 2017

 

CHAIRPERSONS AND SPEAKERS

 

Learn more on the legal aspects by also joining our 13th Legal Affairs Conference (more information click here) which will start the day before (22 March) in the same hotel. A 10% discount will be offered to those registering for both events. If you are interested in attending only in part, please send an email to Lucia Romagnoli by the 10 March 2017 with your request and a tailor-made programme fee will be proposed.

SPONSORS

MEDIA PARTNERS

  logo-gabi  

CONTACT

Lucia Romagnoli
M: +44 (0) 7 562 87 68 73